Nahas Jonathan, Tow Clara Y, Chacko Kristina R, Haider Tehseen, Massoumi Hatef
Penn Medicine, Philadelphia, USA.
Montefiore Medical Center, Division of Hepatology, Bronx, New York, USA.
Gastroenterol Hepatol Bed Bench. 2023;16(1):524-526. doi: 10.22037/ghfbb.v16i1.2639.
To assess the role of granulocyte colony-stimulating factor (GCSF) in the patients with severe alcoholic hepatitis (SAH) using real world experience in the United States.
There are few effective treatments for severe alcoholic hepatitis, which has a significant fatality rate. GCSF has been associated with improved survival in a small number of Indian studies, while there is a dearth of information from other parts of the globe.
We performed a single-center retrospective study of consecutive patients admitted to a tertiary care, liver transplant center with severe alcoholic hepatitis from May 2015 to February 2019. The patients receiving GCSF (5μg/kg subcutaneously every 12 hours for 5 consecutive days) (n=12) were compared to the patients receiving standard of care (n=42).
Thirty-day, 90-day and 1-year mortality rates was similar among groups (25% vs. 17%, P=0.58; 41% vs 29%, P=0.30; 41% vs 47%, P=0.44, respectively). There was no difference in liver transplant listing and orthotopic transplantation among groups.
In this real-world, United States-based study, GCSF does not improved survival in the patient with several alcoholic hepatitis compared to standard of care.
利用美国的实际经验评估粒细胞集落刺激因子（GCSF）在重症酒精性肝炎（SAH）患者中的作用。
重症酒精性肝炎的有效治疗方法很少，其死亡率很高。在少数印度研究中，GCSF与生存率提高有关，而全球其他地区的相关信息较少。
我们对2015年5月至2019年2月在一家三级医疗肝脏移植中心收治的重症酒精性肝炎连续患者进行了单中心回顾性研究。将接受GCSF（每12小时皮下注射5μg/kg，连续5天）的患者（n = 12）与接受标准治疗的患者（n = 42）进行比较。
各组的30天、90天和1年死亡率相似（分别为25%对17%，P = 0.58；41%对29%，P = 0.30；41%对47%，P = 0.44）。各组在肝移植登记和原位移植方面没有差异。
在这项基于美国的实际研究中，与标准治疗相比，GCSF并未提高重症酒精性肝炎患者的生存率。
